





**Fig. S2. Efficacy of dupilumab in atopic dermatitis (AD) according to (A) clinical course (continuous type, recurrent type, or adult-onset type) or (B) clinical findings (general type, facial type or prurigo type).** Individual changes in items associated with the severity of AD from before to after 16 weeks treatment with dupilumab are shown. Red lines: median values. EASI: Eczema Area and Severity Index; POEM: Patient-Oriented Eczema Measure; NRS: numerical rating scale.